No Improvement in OS or PFS from Sacituzumab Govitecan Compared with Chemotherapy In Pretreated Patients with Advanced Urothelial Cancer By Ogkologos - March 24, 2025 642 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TROPiCS-04 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Thank you! March 22, 2021 Remodeled CAR T-Cell Therapy Reduces Side Effects in First Clinical Trial February 20, 2020 Adjuvant Nivolumab Plus Ipilimumab Combination Does Not Improve RFS Over Nivolumab... October 4, 2022 Active Monitoring Promising for Women with Low-Risk Ductal Carcinoma In Situ January 8, 2025 Load more HOT NEWS Teen’s Innovative “SMART Armour” Protects Breast Cancer Patients from Radiation Zucchini everywhere Ralph, Medical Dog, Retires From Colorado Children’s Hospital To Focus On... Dress up that Salad!
